Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hyperlipoproteinemia Clear all
Completed No phase listed Observational

Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers

NCT01138371
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
LDL Apheresis
Procedure
Lead sponsor
Emory University
Other
Eligibility
3 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Phase 4 Interventional

Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation

NCT00974272
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions
Exenatide, Normal Saline
Drug · Other
Lead sponsor
Carl T. Hayden VA Medical Center
Federal
Eligibility
35 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 9, 2009 · Synced Jul 23, 2026, 2:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis

NCT01019200
View directory record Official record
Conditions
Psoriasis, Cardiovascular Diseases, Dyslipidemia
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 80 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Jul 23, 2026, 2:58 PM EDT
Not yet recruiting Not applicable Interventional

Duke Cardiometabolic Prevention Clinic's Impact on High-risk Cardiovascular Patients With Uncontrolled Risk Factors

NCT07117695
View directory record Official record
Conditions
ASCVD, Hyperlipidemia, Hypertension
Interventions
Referral to the Duke Cardiometabolic Prevention Clinic
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Phase 3 Interventional

Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone.

NCT00136981
View directory record Official record
Conditions
Hypercholesterolemia, Familial, Hyperlipidemia
Interventions
torcetrapib/atorvastatin, atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
7
States / cities
Hartford, Connecticut • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone

NCT00910988
View directory record Official record
Conditions
Hyperglycemia, Hyperlipidemia
Interventions
Olanzapine, Ziprasidone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Phase 2 Interventional

Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia

NCT00810979
View directory record Official record
Conditions
Hyperlipidemia
Interventions
SLx-4090, Placebo, Statin
Drug · Other
Lead sponsor
Response Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
19
States / cities
Birmingham, Alabama • Tempe, Arizona • Tucson, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jul 23, 2026, 2:58 PM EDT
Terminated Phase 3 Interventional Results available

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

NCT01975389
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
bococizumab (PF-04950615), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
10,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
518
States / cities
Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 328 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects

NCT02208284
View directory record Official record
Conditions
Healthy
Interventions
PF-06427878, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3561774 in Participants With Mixed Dyslipidemia

NCT05256654
View directory record Official record
Conditions
Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia
Interventions
LY3561774, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Waterbury, Connecticut • Oxon Hill, Maryland • Fall River, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Jul 23, 2026, 2:58 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Using a Telehealth and Shared Decision-Making Model to Address Preventative Medicine Strategies Among Communities in Louisiana

NCT05676970
View directory record Official record
Conditions
Preventative Medicine
Interventions
Telehealth: Personalized Preventative Medicine Strategies, TeleHealth: Preventative Medicine Education
Behavioral
Lead sponsor
Xavier University of Louisiana.
Other
Eligibility
18 Years to 55 Years
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Phase 3 Interventional

A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides

NCT00134498
View directory record Official record
Conditions
Hypertriglyceridemia, Hyperlipoproteinemia Type IV
Interventions
torcetrapib/atorvastatin, atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
39
States / cities
Anaheim, California • Huntington Beach, California • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2007 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects

NCT02676596
View directory record Official record
Conditions
Hyperlipidemia
Interventions
K-312 10 mg QD, K-312 25 mg QD, K-312 50 mg QD, K-312 100 mg QD, K-312 200 mg QD, K-312 400 mg QD, Placebo
Drug · Other
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Phase 3 Interventional Results available

Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

NCT05425745
View directory record Official record
Conditions
Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Lipid Metabolism Disorder, Metabolic Disease, Lipid Metabolism, Inborn Errors, Genetic Disease, Inborn, Hyperlipoproteinemias
Interventions
Obicetrapib, Placebo
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
20
States / cities
Jonesboro, Arkansas • Toluca Lake, California • Sarasota, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Phase 2 Interventional

Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

NCT00280995
View directory record Official record
Conditions
Hypercholesterolemia, Familial
Interventions
ISIS 301012
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Chicago, Illinois • New York, New York • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Jul 23, 2026, 2:58 PM EDT
Completed No phase listed Observational

Equitable Implementation of Cascade Screening for Familial Hypercholesterolemia

NCT05430191
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
Cascade Screening
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Phase 3 Interventional Results available

Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia

NCT00943306
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
lomitapide
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Los Angeles, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Not applicable Interventional

Prevention Trial to Achieve Cardiovascular Targets

NCT01642355
View directory record Official record
Conditions
Coronary Artery Disease, Peripheral Arterial Disease, Hyperlipidemia, Hypertension, Diabetes, Prediabetes, Obesity
Interventions
Prevention Consult, Consult & Behavioral Intervention
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 99 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2017 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Not applicable Interventional

Improving Quality With Outpatient Decision Support

NCT00225628
View directory record Official record
Conditions
Diabetes Mellitus, Coronary Artery Disease, Osteoporosis, Hypertension, Hyperlipidemia
Interventions
Computerized Reminders Medications Monitoring, Computerized Test Results Management Application, Computerized Reminders Hypertension Management, Computerized Reminders Osteoporosis Screening and Mgt
Behavioral
Lead sponsor
Agency for Healthcare Research and Quality (AHRQ)
Federal
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2005 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Phase 4 Interventional

Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care

NCT00345657
View directory record Official record
Conditions
Hyperlipidemia, Mixed Hyperlipidemia, Dyslipidemia
Interventions
Niacin Extended Release/Lovastatin
Drug
Lead sponsor
In His Image
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 27, 2006 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Phase 3 Interventional

Pharmacy Interventions to Improve Chronic Disease Medication Refill

NCT00469365
View directory record Official record
Conditions
Diabetes, Hypertension, Hyperlipidemia, Heart Diseases, Depression, Psychoses
Interventions
pharmacist contact with the patient via telephone, Pharmacist contact with the patient's physician via fax, Usual care
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
Not listed
Enrollment
3,048 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2008 · Synced Jul 23, 2026, 2:58 PM EDT
Completed No phase listed Observational

Longitudinal Study in Perimenopausal Women With Risk Factors for Atherosclerosis

NCT00921011
View directory record Official record
Conditions
Atherosclerosis
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
40 Years and older · Female only
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jul 23, 2026, 2:58 PM EDT
Enrolling by invitation Not applicable Interventional

Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors

NCT06834204
View directory record Official record
Conditions
Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer, Prostate Cancer (Adenocarcinoma), Endometrial Cancer, Hypertension, Hyperlipidemia (E.G., Hypercholesterolemia), Diabetes Mellitus
Interventions
PC2: Primary Care Connect
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor

NCT01556906
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
Lomitapide
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
13 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Jul 23, 2026, 2:58 PM EDT